Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LLY, GILD, MRK)

With the spotlight firmly on Covid variants, it’s easy to lose sight of what will probably be the most important segment of the biopharma space over the next ten years: oncology. This is where the biggest success stories will be found. It’s where the largest revolutions will happen. It’s the epicenter of the most important […]

How to Invest in the $111 Billion Diabetes Boom (DXCM, ATRX, TNDM, MNKD, NVO, LLY)

The global diabetes market was estimated at $25.9 billion in 2020 and is expected to reach $28.5 billion in 2021 according to Grand View Research. The global market for diabetes care products including drugs and devices is even more impressive. This larger category is expected to exceed $111.2 billion by 2027 according to iHealthcareAnalyst.com. Why […]

OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) Presents Interesting Picture as a Bite-Size Buyout Candidate

OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) is in an interesting phase of its existence. The company just solidified its sense of credibility in the space with a recent announcement of a productive meeting with top staffing scientists at the host hospital of the Company’s upcoming Phase 2 trial of ProscaVax for prostate cancer. That represents the first […]

Eli Lilly & Co. (NYSE:LLY): Strong Product and Cost Cutting Lead To Better Earnings

Boston, MA 10/31/2013 (wallstreetpr) – Eli Lilly & Co. (NYSE:LLY) new strategy helped the company to raised better earnings than was expected by Wall Street. The two major components of this result was cost cutting and growth of a strong drug for depression, diabetes, and cancer. The company earned $1.20 million, or $1.11 per share, that […]